Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study - Quiz - MDSpire

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

  • By

  • Marta Codirenzi

  • Federica Davanzo

  • Luca Iorio

  • Eleonora Fiorin

  • Gabriella Guarnieri

  • Fulvia Chieco Bianchi

  • Alessia Achille

  • Maria Rita Marchi

  • Andrea Vianello

  • Andrea Doria

  • Roberta Ramonda

  • Roberto Padoan

  • June 15, 2026

  • 0 min

Share

Original Source(s)

Comparative real-world effectiveness and safety of benralizumab and two mepolizumab dosing regimens in eosinophilic granulomatosis with polyangiitis: a 24-month prospective single-center cohort study

  • by Marta Codirenzi, Federica Davanzo, Luca Iorio, Eleonora Fiorin, Gabriella Guarnieri, Fulvia Chieco Bianchi, Alessia Achille, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberta Ramonda, Roberto Padoan

  • June 15, 2026

Related Content

Case report: When Behçet’s disease meets multizonal outer retinopathy and retinal pigment epitheliopathy: longitudinal multimodal imaging of an overlap phenotype

HLA-DRB1*15:01 drives sex- and age-dependent microglial immune phenotypes and neuroimmune signaling

Research landscape, hotspots, and evolutionary trends of knee osteoarthritis and oxidative stress: a multidimensional bibliometric analysis